<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/455203A4-9781-4725-A589-223CA5AD2E10"><gtr:id>455203A4-9781-4725-A589-223CA5AD2E10</gtr:id><gtr:name>Australian National University (ANU)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/529BA57C-BA0B-4947-A462-83A9DAED55B1"><gtr:id>529BA57C-BA0B-4947-A462-83A9DAED55B1</gtr:id><gtr:name>University of Toulouse</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Centre for Infection &amp; Immunity</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/455203A4-9781-4725-A589-223CA5AD2E10"><gtr:id>455203A4-9781-4725-A589-223CA5AD2E10</gtr:id><gtr:name>Australian National University (ANU)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/529BA57C-BA0B-4947-A462-83A9DAED55B1"><gtr:id>529BA57C-BA0B-4947-A462-83A9DAED55B1</gtr:id><gtr:name>University of Toulouse</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/853FADB2-B00C-4D11-8D75-943C25B91E97"><gtr:id>853FADB2-B00C-4D11-8D75-943C25B91E97</gtr:id><gtr:firstName>Konstantin</gtr:firstName><gtr:surname>Panov</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801834"><gtr:id>CB8EE62E-327C-451F-AAC7-CCDE17603126</gtr:id><gtr:title>The role of Topoisomerase II-alpha in regulated transcription of human ribosomal RNA genes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801834</gtr:grantReference><gtr:abstractText>Synthesis of proteins is absolutely essential for any known form of life. It is carried out by cellular organelles named ribosomes, one of the most incredible cellular machines, frequently referred to as protein factories. The ribosomal RNA (rRNA) is the key building block of the ribosomes and rRNA is essential to both their structure and function. The synthesis of rRNA (also known as transcription) is the key regulator of ribosome production and fundamental to life. The transcription of ribosomal RNA is tightly linked to cell growth and division and when deregulated could have a dramatic effect on the cell s fate, leading to cell death or defects which might result in oncogenic transformation. An elevated level of rRNA synthesis supports the unrestrained proliferation of cancer cells and rRNA transcription therefore represents a valid target for anticancer therapy.
In the proposed research, we will use various biochemical approaches to study the mechanism of rRNA transcription and will focus on the role of topoisomerase-II, one of the most amazing enzymes, in the regulation of rRNA transcription in human cells. Topoisomerases, these magicians of DNA world are targets for a number of highly successful anticancer drugs and a key target for development of better therapeutics.
The proposed research would therefore bring together two areas of high interest and importance and will contribute to the development of a new generation of drugs, targeting diseases associated with hyperproliferation and abnormal cell size including cancer and heart diseases. Moreover, drugs selectively targeting rRNA synthesis in cells could be used for stimulation of cell growth and proliferation in cell-replacement therapy strategies to the benefit of those with degenerative cell diseases.</gtr:abstractText><gtr:technicalSummary>The level of ribosomal RNA (rRNA) synthesis by RNA polymerase-I (Pol-I) is rate-limiting to ribosome biogenesis and it makes Pol-I transcription fundamental to life. The production of rRNA is tightly linked to cell growth and proliferation and when deregulated can have a dramatic effect on the fate of a cell. An elevated level of rRNA synthesis is an indicator of the proliferative (hence aggressive) state of tumour cells and is required to support an unrestrained proliferation of these cells. Therefore Pol-I transcription is a potential target for anticancer therapy. DNA topoisomerase-IIalpha (TopoIIa) is a member of the Type-II DNA topoisomerase family of ubiquitous, highly conserved enzymes that catalyse the passage of one double-stranded segment of DNA through another. Type-II topoisomerases play important roles in a number of fundamental cellular processes including chromosome replication and segregation, transcription, and cell cycle regulation. Topo-II enzymes are targets for a number of highly successful anticancer drugs and a key target for development of better therapeutics.
We have recently shown that TopoIIa is a part of the initiation competent form of Pol-I, interacts with transcription factor RRN3 and associates with rDNA repeats in human cells. This association correlates with the level of Pol-I transcription and formation of pre-initiation complexes suggesting a role of TopoIIa in transcription of rRNA genes. Moreover, TopoIIa inhibitors affect activation of rRNA gene transcription whereas they have little effect on steady-state levels. 
The proposed project aims to study structural and functional roles of TopoIIa in Pol-I transcription. We will investigate the significance TopoIIa-RRN3 interactions and define interacting domains using a variety of in vitro and in vivo based assays. We will determine the role of TopoIIa ?RRN3 interaction in assembly and functioning of Pol-I and investigate the role of topoisomerase activity in assembly of the Pol-I complex. We will investigate a mechanism of activation of rRNA gene transcription and the role of topoisomerase activity in pre-initiation complex formation, transcription initiation and in recruitment of factors facilitating transcription.
In this project we bring together two important areas of biological research, both with direct relevance to anticancer therapy and diagnostics. Apart from its fundamental scientific importance, detailed understanding of role of TopoIIa in the control of rRNA production will be directly applicable to the design and development of novel drugs targeting diseases associated with hyperproliferation and abnormal cell size including cancer and heart diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>363656</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>A. Porter</gtr:description><gtr:id>24CEEBB2-2742-4EB6-8865-F54CC57C7D7F</gtr:id><gtr:impact>A manuscript submitted for publication</gtr:impact><gtr:outcomeId>eDpHaYHj6Xk-1</gtr:outcomeId><gtr:partnerContribution>AP group constructed the conditional Top2-alpha expressing cell line (HTETOP) derivatives and Top2-alpha expression constructs. AP help to wrote the paper.</gtr:partnerContribution><gtr:piContribution>We conceived the project, designed the and executed most of experiments and with help from other authors wrote the paper</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Toulouse</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Department of Molecular Biology</gtr:department><gtr:description>O. Gadal</gtr:description><gtr:id>D97CE920-133D-4ADB-8EDA-F618FDB2165B</gtr:id><gtr:impact>A manuscript submitted for publication</gtr:impact><gtr:outcomeId>fiRdBph78cN-1</gtr:outcomeId><gtr:partnerContribution>O.G. group designed and performed all experiments in yeast model system</gtr:partnerContribution><gtr:piContribution>We conceived the project, designed the and executed most of experiments and with help from other authors wrote the paper</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Australian National University (ANU)</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Ross Hannan</gtr:description><gtr:id>B2765190-E24A-454D-8F9D-5E0FBF8DAF84</gtr:id><gtr:impact>Dr Panov has been recently awarded an International Exchanges award by the Royal Society to fund his visit to ANU.</gtr:impact><gtr:outcomeId>58b93c20dd1a87.00521946-1</gtr:outcomeId><gtr:partnerContribution>My partners provide a funding necessary for performing a number of experiments.</gtr:partnerContribution><gtr:piContribution>The collaboration is based upon my work investigating the roles of TopoII-alpha and KDM4A in the regulation of Pol-I transcription.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pilot Grant</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Breast Cancer Campaign (BCC)</gtr:fundingOrg><gtr:id>CA4F2A6F-3470-40F8-82A3-AEAA3941A2EE</gtr:id><gtr:outcomeId>ZCheqjkr3sV0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8743FD45-CB20-479E-A6EA-ABD03F270E5D</gtr:id><gtr:title>Topoisomerase IIa promotes activation of RNA polymerase I transcription by facilitating pre-initiation complex formation.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fad65768b977156c3a8f8abbb6cc651f"><gtr:id>fad65768b977156c3a8f8abbb6cc651f</gtr:id><gtr:otherNames>Ray S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>HnMdjRTcfkR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>841E33DA-F581-405B-BA60-B4003E50A2EE</gtr:id><gtr:title>The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e82f9147d3c319d359cad874904fc3b"><gtr:id>3e82f9147d3c319d359cad874904fc3b</gtr:id><gtr:otherNames>Johnston R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58b8bea1210117.41353799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A06041C-266E-4810-8B85-9D46C4F923EF</gtr:id><gtr:title>Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e0e6e83522b673e7ecd1a81056813d2"><gtr:id>8e0e6e83522b673e7ecd1a81056813d2</gtr:id><gtr:otherNames>Andrews WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>FNmuT3tAdwf</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801834</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>